A detailed history of Reap Financial Group, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Reap Financial Group, LLC holds 150 shares of GILD stock, worth $16,798. This represents 0.0% of its overall portfolio holdings.

Number of Shares
150
Previous 95 57.89%
Holding current value
$16,798
Previous $7.95 Million 74.73%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 27, 2025

BUY
$83.95 - $97.9 $4,617 - $5,384
55 Added 57.89%
150 $13.9 Million
Q3 2024

Feb 27, 2025

SELL
$66.59 - $83.99 $932 - $1,175
-14 Reduced 12.84%
95 $7.95 Million
Q2 2024

Feb 27, 2025

BUY
$63.15 - $72.88 $252 - $291
4 Added 3.81%
109 $7.51 Million
Q1 2024

Feb 27, 2025

SELL
$71.58 - $87.29 $94,628 - $115,397
-1,322 Reduced 92.64%
105 $7.66 Million
Q4 2023

Feb 27, 2025

BUY
$73.27 - $83.09 $104,556 - $118,569
1,427 New
1,427 $116 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $140B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Reap Financial Group, LLC Portfolio

Follow Reap Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Reap Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reap Financial Group, LLC with notifications on news.